Dyne Therapeutics, Inc. 4

Johanna Friedl-Naderer, CCO of Dyne Therapeutics, Inc., sold 226 shares of common stock on 2026-08-13 to cover taxes from RSU vesting.

On August 13, 2026, Johanna Friedl-Naderer, Chief Commercial Officer of Dyne Therapeutics, Inc., automatically sold 226 shares of the company’s common stock at a weighted average price of approximately $26.28 per share, for total proceeds of about $5,940, solely to cover tax withholding obligations arising from the vesting of previously granted restricted stock units under a pre-arranged Rule 10b5-1 compliant agreement. Following this small, non-discretionary sale, she beneficially owns 153,982 shares of common stock, which includes 119,928 unvested RSUs, and the transaction does not indicate a directional change in her economic exposure to the company.

Filing Facts

CIK

1818794

Ticker

DYN

Form

4

Source Type

fda

Accession

0001915598-26-000004

Alert Tier

5